1216 Neuron23 Westlake EMB Wed 445a ET
BioCentury & Getty Images

Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

Emerging Company Profile: Westlake Village start-up’s partnership with Germany’s Origenis yields candidates against two targets

A partnership with Germany’s Origenis gives the Westlake Village-backed biotech candidates against two targets.

Dec 16, 2020 | 1:49 PM GMT

After two years in

Read the full 666 word article

How to gain access

Continue reading with a
two-week free trial.